Abstract: A device for resolving common-mode voltage interference is applied to a power supply system including a power converter and a switch mechanism. Each phase of an output end of the power converter is connected to a downstream circuit by using the switch mechanism. The switch mechanism includes a first switch and a second switch. The device includes a controller and a passive component. Two ends of the first switch in at least one phase of the output end of the power converter are connected in parallel to the passive component, and the controller controls the second switch to be turned on, and when a voltage difference between the two ends of the first switch is less than a preset voltage, controls the first switch to be turned on. In this manner, the switch mechanism is protected, thereby prolonging a service life of the switch mechanism.

Abstract: A device for resolving common-mode voltage interference is applied to a power supply system including a power converter and a switch mechanism. Each phase of an output end of the power converter is connected to a downstream circuit by using the switch mechanism. The switch mechanism includes a first switch and a second switch. The device includes a controller and a passive component. Two ends of the first switch in at least one phase of the output end of the power converter are connected in parallel to the passive component, and the controller controls the second switch to be turned on, and when a voltage difference between the two ends of the first switch is less than a preset voltage, controls the first switch to be turned on. In this manner, the switch mechanism is protected, thereby prolonging a service life of the switch mechanism.

Abstract: The invention discloses an indenopyrazole small-molecule tubulin inhibitor, which is characterized by having a structure represented by general formula I: wherein R represents NH2 or NHOH; the invention also discloses a preparation method of the indenopyrazole compound, or pharmaceutical salts thereof. The compound of the present invention is an indenopyrazole small-molecule tubulin inhibitor having a novel structure, and has very strong proliferation inhibition activity to human hepatocellular carcinoma (HepG2) cells, human prostate carcinoma (PC3) cells, human cervical carcinoma (HeLa) cells, human breast adenocarcinoma (MCF-7) cells, and human leukemia (K562) cells; the compound is similar to colchicine in mechanism of action, and thus capable of inhibiting tubulin polymerization; the compound is significant for enhancing the specificity and effectiveness of drugs, reducing toxic and side effects, preventing drug tolerance, and so on.

Abstract: The invention discloses an indenopyrazole small-molecule tubulin inhibitor, which is characterized by having a structure represented by general formula I: wherein R represents NH2 or NHOH; the invention also discloses a preparation method of the indenopyrazole compound, or pharmaceutical salts thereof. The compound of the present invention is an indenopyrazole small-molecule tubulin inhibitor having a novel structure, and has very strong proliferation inhibition activity to human hepatocellular carcinoma (HepG2) cells, human prostate carcinoma (PC3) cells, human cervical carcinoma (HeLa) cells, human breast adenocarcinoma (MCF-7) cells, and human leukemia (K562) cells; the compound is similar to colchicine in mechanism of action, and thus capable of inhibiting tubulin polymerization; the compound is significant for enhancing the specificity and effectiveness of drugs, reducing toxic and side effects, preventing drug tolerance, and so on.

Abstract: The invention relates to trehalose derivatives with general formula (I), a preparation method and uses thereof, wherein 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has anti-colon cancer 26-L5 cell invasion activity which is better than that of a natural product Brartemicin, IC50 is 0.10 ?g/mL (0.15 ?M), and when the IC50 is 10 ?g/mL, 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has no cytotoxicity, shows high-selectivity anti-tumor invasion activity and can be used for preparing medicaments for preventing and treating invasion and metastasis of colon cancer and the like.

Abstract: The invention relates to trehalose derivatives with general formula (I), a preparation method and uses thereof, wherein 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has anti-colon cancer 26-L5 cell invasion activity which is better than that of a natural product Brartemicin, IC50 is 0.10 ?g/mL (0.15 ?M), and when the IC50 is 10 ?g/mL, 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has no cytotoxicity, shows high-selectivity anti-tumor invasion activity and can be used for preparing medicaments for preventing and treating invasion and metastasis of colon cancer and the like.